Blueprint Medicines Corporation (NASDAQ:BPMC) went up to recover about 111.61% since recording its record low price of $44.58. The stock experienced 1.75% jump, arriving at $94.33 on 6/28/2019. During the day, the stock price traveled from $92.56 to $95.2. This company shares are 18.87% off its target price of $112.13 and the current market capitalization stands at $4.53B. The recent change has given its price a 14.32% lead over SMA 50 and -6.38% deficit over its 52-week high. The stock witnessed 20.61% gains, 17.84% gains and 86.35% gains for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found BPMC’s volatility during a week at 3.55% and during a month it has been found around 4.99%.

Blueprint Medicines Corporation (BPMC) Top Holders

Institutional investors currently hold around $4.57 billion or 95% in BPMC stock. Look at its top three institutional owners: Fmr Llc owns $654.58 million in Blueprint Medicines Corporation, which represents roughly 14.45% of the company’s market cap and approximately 14.31% of the institutional ownership. Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 3,959,505 shares of the stock are valued at $373.5 million. The third largest holder is Blackrock Inc., which currently holds $320.64 million worth of this stock and that ownership represents nearly 7.08% of its market capitalization.

Blueprint Medicines Corporation 13F Filings

At the end of March reporting period, 114 institutional holders increased their position in Blueprint Medicines Corporation (NASDAQ:BPMC) by some 5,839,100 shares, 73 decreased positions by 3,160,151 and 26 held positions by 39,486,181. That puts total institutional holdings at 48,485,432 shares, according to SEC filings. The stock grabbed 49 new institutional investments totaling 2,534,955 shares while 9 institutional investors sold out their entire positions totaling 54,917 shares.

Blueprint Medicines Corporation (NASDAQ:BPMC) Insider Trades

Multiple company employees have indulged in significant insider trading. Blueprint Medicines Corporation disclosed in a document filed with the US Securities and Exchange Commission (SEC) that Director Rowland Charles A Jr has sold 11,818 shares of Blueprint Medicines Corporation (BPMC) in the trading session dated Jun. 20, 2019. These shares are worth $1,124,483 and were traded at $95.15 each. The SEC filing shows that Dorsch Marion performed a sale of 4,600 shares. The Chief Scientific Officer disposed these shares by way of transaction on Jun. 17, 2019. The company’s shares were given away at $99 per share worth to an income of some $455,400 to the account of Dorsch Marion.

COO, Haviland Kate, sold 11,952 common shares of Blueprint Medicines Corporation (BPMC) in the open market. In a transaction dated Jun. 17, 2019, the shares were put up for sale at an average price of $96.46, raking in a sum of $1,152,890. After this sale, 5,874 common shares of BPMC are directly owned by the insider, with total stake valued at $554,094.

In the transaction dated Jun. 17, 2019, a great number of shares sold came courtesy the CEO and President; Albers Jeffrey W. disposed a total of 5,000 shares at an average price of $99.06, amounting to approximately $495,300. The insider now directly owns 28,961 shares worth $2,731,891.

Blueprint Medicines Corporation (BPMC) Analyst Guide

Several analysts have released their opinion on Blueprint Medicines Corporation (NASDAQ:BPMC), with 5 analysts believing it is a strong buy. Whereas 0 of them predict the stock is a hold. Also, there are 4 buy, 0 sell and 0 strong sell ratings, collectively assigning a 1.44 average brokerage recommendation [T1].